OpenAlex · Aktualisierung stündlich · Letzte Aktualisierung: 30.03.2026, 14:53

Dies ist eine Übersichtsseite mit Metadaten zu dieser wissenschaftlichen Arbeit. Der vollständige Artikel ist beim Verlag verfügbar.

Bridging the Future: Perspectives of a Multinational Group of Nephrologists on Artificial Intelligence (AI) in CKD Management

2024·0 Zitationen·Journal of the American Society of Nephrology
Volltext beim Verlag öffnen

0

Zitationen

7

Autoren

2024

Jahr

Abstract

Background: Artificial intelligence (AI) techniques, particularly machine learning (ML) and deep learning, have made significant strides in predicting and diagnosing chronic kidney disease. This study aims to explore the perceptions of a multinational group of nephrologists regarding the application of AI in clinical practice. Understanding their views is crucial for the integration of AI in nephrology. Methods: A prospective, observational study was conducted in March 2024, involving nephrologists from 17 countries across four continents, all affiliated with a large hemodialysis provider. The survey, validated by 6 nephrologists, comprised 8 technical questions using a 5-point Likert scale, with 1 corresponding to "totally disagree" and 5 to "totally agree." Demographic data were also collected. Results presented as mean±standard deviation or proportions, as appropriate. T-test was used for statistical analysis, with a p-value below 0.05 considered statistically significant. Results: Among the 196 valid responses, 80% of nephrologists recognized the term "AI," and 65% were familiar with "ML." Nephrologists acknowledge the potential of AI in the future but currently rely more on traditional tools to support the clinical decision-making process (3.74±1.14 vs. 3.12±1.07, p<0.05). This reliance on traditional tools is more evident among nephrologists not familiar with the term “ML” (3.90±0.93 vs. 3.09±1.01, p<0.05). When asked about the advantages of AI and ML in supporting clinical decision-making, the highest score was attributed to “simplification of decision algorithms” (3.82±1.10). Interestingly, nephrologists without previous contact with AI-supported decision-making tools considered the role of AI less significant in “assisting in making decisions, allowing concentration on high-value activities”, compared to those with previous experience in this area (3.38±1.22 vs. 3.88±0.97, p<0.05). Conclusion: Enhancing the understanding of AI can facilitate the integration of these technologies into nephrology practice, benefiting patient care. Given the perceived potential of AI in managing different types of CKD patients, efforts to promote AI literacy in the nephrology community may be fundamental for the adoption of these tools in regular clinical practice.

Ähnliche Arbeiten

Autoren

Institutionen

Themen

Artificial Intelligence in Healthcare and EducationRenal and Vascular PathologiesRenal cell carcinoma treatment
Volltext beim Verlag öffnen